ArticleResearch (Washington, D.C.)2026
Multisite Chronic Pain Reveals Neuro-Immune-Metabolic Dysregulation across Rheumatoid Arthritis and Depression.
Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multisite chronic pain (MCP) frequently co-occurs with immune and depressive disorders, yet whether it reflects coordinated cross-domain multi-omic dysregulation remains unknown. Using UK Biobank data (19,484 baseline participants; 32,870 to 399,476 for 15.9-year follow-up), we identified MCP-related multi-omic signatures spanning 59 biochemical measures, 168 metabolites, and 2,920 proteins. Notably, these signatures showed graded dysregulation [controls < depression < rheumatoid arthritis (RA) < comorbidity] with increasing disease burden, were associated with increased risk of incident RA and depression, and partially mediated their bidirectional association. We further identified HNMT as a depression risk factor, FGF21 as an RA risk factor, MME as a depression protective factor, and platelet count/FGF21/HNMT as shared factors using Mendelian randomization. Beyond disease outcomes, the signatures were associated with brain structural impairment and health-related behaviors (smoking/fish intake/physical activity), and aligned with polygenic liability for immune-metabolic-psychiatric traits. Together, these findings demonstrate that MCP reflects coordinated neuro-immune-metabolic dysregulation underlying RA-depression comorbidity and functions as a systems-level phenotype linking immune processes and depression.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.